Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides a comprehensive set of chimeric antigen receptors-macrophages (CAR-MA) assays to support the development of one or more CAR-MA therapy programs. The success of CAR expression is an important step in the development of CAR-based cell therapy. We provide accurate and reproducible in vitro and in vivo CAR expression detection methods.
CARs are genetically engineered receptors that can recognize specific antigens and subsequently activate downstream signaling. These receptors can be artificially expressed in human T cells, NK cells, or macrophages using gene transfer techniques, such as lentiviral transduction. CAR-MA kills tumor cells through CAR targeting and exerts targeted phagocytosis, as well as remodeling the tumor microenvironment by inducing inflammation and recruiting T cells.
Evaluating CAR expression is an essential step in the production of CAR cells. This is often done by flow cytometry, using protein L, anti-Fab antibodies or target antigens as detection methods. Among these common choices, target antigens are widely considered to be the best option, because it offers high specificity and minimal background staining. In vitro visualization methods, including confocal and total internal reflection fluorescence microscopy, have captured the molecular details underlying CAR immunological synapse formation, signaling, and cytotoxicity. An important step for CAR-MA therapy is to evaluate CAR expression in vivo. In vivo tracking methods, including two-photon microscopy, bioluminescence imaging (BLI), and positron emission tomography scanning (PET), have been used to monitor CAR-cells' biodistribution across blood, tissue, and tumor.
Fig.1 CAR detection methods across multiple levels. (Hu, 2020)
Creative Biolabs provides diverse methods for CAR expression detection, employing proteins and antibodies. We have produced a comprehensive collection of recombinant proteins to support the development of CAR-MA therapy. This list of recombinant proteins includes a number of pre-biotinylated proteins and fluorescent-labeled target antigens that are exclusively suitable for evaluating CAR expression. Antibodies that detect CAR can be used in Western Blot, flow cytometric analysis, Immunohistochemistry, ELISA, Immunohistochemistry, and Immunocytochemistry.
Fig.2 CAR detection services. (Creative Biolabs)
Creative Biolabs now offers world-leading CAR-MA services. If you have any customized requests for CAR expression detection, please don't hesitate to contact us.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
